Brookfield Resumes Talks with Grifols Over Potential Offer

Published 24 days agoBAM

Brookfield Resumes Talks with Grifols Over Potential Offer

Brookfield Asset Management has reignited discussions with Spanish plasma company Grifols regarding a potential acquisition. This comes after Brookfield's initial bid was rejected last year. The new round of negotiations suggests Brookfield remains interested in leveraging opportunities within the plasma industry despite previous setbacks.

According to prior reports, Grifols' board dismissed Brookfield's non-binding offer in November 2024, which valued the firm at around €6.45 billion. The offer was critiqued for not reflecting Grifols' anticipated long-term growth potential. Currently, discussions involve Brookfield representative Tristan Tully communicating with Grifols' founding family, while Morgan Stanley advises on any forthcoming bids.

Amid these talks, Grifols is navigating challenging corporate dynamics, including a previous short-seller assault questioning its financial reporting, which contributed to share price volatility. Nevertheless, Grifols has achieved a milestone with the FDA's approval of its drug Yimmugo and aims to optimize its operational efficiency while managing its debt burden. Any future proposal from Brookfield will need to adequately address Grifols' valuation expectations to facilitate a successful agreement.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Encompass Health Raises 2025 Revenue Guidance with Strategic Expansion

Encompass Health Raises 2025 Revenue Guidance with Strategic Expansion

Encompass Health Corporation has revised its 2025 revenue guidance upwards, now projecting net operating revenue between $5.85 billion and $5.925 billion. This adjustment comes as the company anticipates stronger financial performance compared to its February 2025 forecast, which estimated revenue at $5.8 billion to $5.9 billion. Supporting this optimistic outlook, Encompass Health expects its adjusted EBITDA to fall between $1.16 billion and $1.2 billion. Furthermore, the company's guidance for adjusted earnings per share, from continuing operations, is set to range from $4.67 to $4.96. According to Nasdaq.com, these enhancements are underpinned by the company's growth strategies, as indicated by a projected 8.9% increase in revenue compared to 2024. Key to this growth strategy, Encompass Health plans to expand its operations by opening seven new hospitals and increasing capacity by 340 beds in 2025. Such initiatives are central to achieving the newly set revenue targets, as the company continues to focus on enhancing its services and market reach.

Leapmotor to Supply EV Platforms for Hongqi Models

Leapmotor to Supply EV Platforms for Hongqi Models

Leapmotor, a Chinese electric vehicle manufacturer, has announced a partnership with the FAW Group to provide its B10 EV platform for the development of Hongqi-branded electric vehicles. As reported by Reuters, this collaboration will enable Hongqi to produce both pure electric and range-extended models using Leapmotor's advanced EV technology. The partnership aims to target a range of international markets including Europe, the United Kingdom, Australia, New Zealand, and the Middle East. Production of these new Hongqi models is slated to begin in the latter half of 2026 at Leapmotor's Hangzhou facility in eastern China. This geographic expansion is significant as it marks a concerted effort to broaden Hongqi's global footprint through a blend of technological innovation and distinctive design. Leapmotor's CEO underscored the importance of this collaboration in enhancing the global competitiveness of Hongqi vehicles. Moreover, according to Reuters, Leapmotor is also in talks with Ferrari to explore the development of a new model on its EV architecture, showcasing the company's broadening influence and appeal in the automotive sector.

No Public Reports on Acuren Corp's Interest in NV5 Global Inc.

No Public Reports on Acuren Corp's Interest in NV5 Global Inc.

6 hours agoNVEE

As of April 26, 2025, there have been no public announcements or reports confirming that Acuren Corp. is interested in a takeover of NV5 Global Inc. This absence of information suggests that if such discussions are occurring, they are not yet disclosed to the public. Consulting official channels and financial news outlets is recommended for the most accurate updates. According to available sources, neither Acuren Corp. nor NV5 Global Inc. have released official statements regarding any potential merger or acquisition plans. The lack of public disclosure points to the possibility that either there is no transaction forthcoming, or that any negotiations are still confidential. Both Acuren Corp. and NV5 Global Inc. have maintained silence on this matter. While companies might explore various strategies to enhance growth or market reach, official confirmations or press releases are crucial for stakeholders monitoring such significant corporate developments.

Unilever Requests Dismissal of Ben & Jerry's CEO Lawsuit

Unilever Requests Dismissal of Ben & Jerry's CEO Lawsuit

Unilever has filed a motion to dismiss a lawsuit from Ben & Jerry’s concerning the alleged ousting of its CEO, David Stever. Unilever firmly denies any involvement in Stever's resignation, asserting that he voluntarily left his position on March 31 after declining a global role within Unilever's ice cream division, as reported by Reuters. Ben & Jerry's alleges that Unilever attempted to undermine its executive board and curtail its political activism. This includes actions such as the company's stance against the war in Gaza and criticisms directed at former U.S. President Donald Trump. The root of the legal battle lies in a 2000 agreement meant to preserve Ben & Jerry's independence following its acquisition by Unilever, with the lawsuit lodged in November 2024 claiming a breach of this agreement, according to Time. In response to the allegations, Unilever maintains that Ben & Jerry's has shifted towards advocacy on controversial and polarizing issues, posing risks to the company's reputation and its employees. While seeking to dismiss the lawsuit, Unilever also outlines its broader corporate strategy, which includes plans to spin off its ice cream division—encompassing brands like Breyers and Magnum—by July 1, 2025, to refine its brand portfolio.